Novavax COVID-19 Vaccine

by David O. Freedman, M.D. last updated 2022-02-19 15:23:53.237054-05:00 © Antimicrobial Therapy, Inc.
Nuvaxovid, Covovax, NVX-CoV2373



  • Novavax COVID-19 Vaccine (Nuvaxovid, Covovax (India), NVX-CoV2373)

Authorized for Use in

  • UK, India, EU EMA, WHO EUL, Meets US Entry Requirements; US FDA EUA application has been submitted.


  • ≥ 18 yrs


  • Recombinant protein subunit, adjuvanted

Primary Dosing

  • 0.5 ml IM (5 ug), 2 doses 21 days apart

Booster Dosing

  • No recommendation at present


  • No manufacturer data available on the interchangeability of Nuvaxovid with other COVID-19 vaccines to complete the primary vaccination course.  In vitro Novavax vaccine shows boosts neutralizing response after primary series with Pfizer vaccine or AstraZeneca vaccine.
  • May be promoted in the US as a booster dose capable of broadening immune repertoire against variants


  • 2-8°C (36-46°F) for up to 9 months; protect from light


Overall against symptomatic disease

  • All adults: 90.4%, 7 days after dose 2; Age 18-64 yrs: 89.8%

Real world against hospitalization

  • No real word experience at present

Age > 65 years

  • 88.9%


  • No data at present

Against severe disease / death

  • Phase 3 trial: Adults: 100%, 7 days after dose 2

Against asymptomatic infection / transmission

  • No data

Duration of efficacy after final dose

  • No data



  • Hypersensitivity to the active substance or to any vaccine ingredients


  • Awaiting FDA EUA ruling

Adverse effects

  • Local and systemic adverse reactions more frequently after Dose 2 than after Dose 1.  Increased by co-administration of influenza vaccine. Fatigue, myalgia, headache, malaise, each in approximately 50%

Special Needs Populations


  • Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryo/fetal development, parturition, or post-natal development. Use if benefits outweight risk.

Immunocompromised / HIV

  • No data